Solid Biosciences（纳斯达克代码：SLDB）近日宣布，其针对杜氏肌营养不良症（DMD）研发的SGT-003基因疗法，在与美国食品药品监督管理局（FDA）举行的C类会议中获得了积极反馈。这一关键进展为该项目后续的临床开发计划清除了重要监管障碍。
FDA对SGT-003现有的临床前数据包表示了认可，并就下一阶段的临床试验设计提供了建设性指导。此次积极的监管互动标志着SGT-003项目向前迈出了实质性的一步，增强了其治疗DMD这一严重遗传性疾病的潜力。公司计划基于此次会议反馈，加快推进SGT-003的临床开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.